Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Alten

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Annals of Hematology|February 21, 2020
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemiaMaximilian Schieck, Jana Lentes, Kathrin Thomay, et al.
Hemasphere|June 5, 2023
Hypersensitivity Reactions to Native Anja Möricke, Carmelo Rizzari, Julia Alten, et al.
Leukemia|August 6, 2022
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like diseaseJan Zuna, Lenka Hovorkova, Justina Krotka, et al.
Leukemia|May 14, 2024
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelinesVincent H J van der Velden, Isabel Dombrink, Julia Alten, et al.
Molecular Cancer|July 5, 2024
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patientsLenka Hovorkova, Lucie Winkowska, Justina Skorepova, et al.
International Journal of Cancer|March 27, 2020
PTPN11 mutations in canine and human disseminated histiocytic sarcomaBenoit Hédan, Mélanie Rault, Jérôme Abadie, et al.
Blood|March 25, 2025
NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturationMichaela Kotrova, Constantin Proske, Nikos Darzentas, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 13, 2023
Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study groupStefanie V Junk, Elke Schaeffeler, Martin Zimmermann, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolJanine Stutterheim, Inge M van der Sluis, Paola de Lorenzo, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Annals of Hematology|February 21, 2020
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemiaMaximilian Schieck, Jana Lentes, Kathrin Thomay, et al.
Hemasphere|June 5, 2023
Hypersensitivity Reactions to Native Anja Möricke, Carmelo Rizzari, Julia Alten, et al.
Leukemia|August 6, 2022
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like diseaseJan Zuna, Lenka Hovorkova, Justina Krotka, et al.
Leukemia|May 14, 2024
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelinesVincent H J van der Velden, Isabel Dombrink, Julia Alten, et al.
Molecular Cancer|July 5, 2024
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patientsLenka Hovorkova, Lucie Winkowska, Justina Skorepova, et al.
International Journal of Cancer|March 27, 2020
PTPN11 mutations in canine and human disseminated histiocytic sarcomaBenoit Hédan, Mélanie Rault, Jérôme Abadie, et al.
Blood|March 25, 2025
NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturationMichaela Kotrova, Constantin Proske, Nikos Darzentas, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 13, 2023
Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study groupStefanie V Junk, Elke Schaeffeler, Martin Zimmermann, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolJanine Stutterheim, Inge M van der Sluis, Paola de Lorenzo, et al.
Pageof 4